Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin

Thangirala Sudha; Murat Yalcin; Hung Yun Lin; Ahmed M. Elmetwally; Tipu Nazeer; Thiruvengadam Arumugam; Patricia Phillips; Shaker A. Mousa

doi:10.1016/j.canlet.2014.04.016

Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin

Thangirala Sudha, Murat Yalcin, Hung Yun Lin, Ahmed M. Elmetwally, Tipu Nazeer, Thiruvengadam Arumugam, Patricia Phillips, Shaker A. Mousa

Research output: Contribution to journal › Article › peer-review

29 Citations (Scopus)

Abstract

Sulfated non-anticoagulant heparins (S-NACHs) might be preferred for potential clinical use in cancer patients without affecting hemostasis as compared to low molecular weight heparins (LMWHs). We investigated anti-tumor effects, anti-angiogenesis effects, and mechanisms of S-NACH in a mouse model of pancreatic cancer as compared to the LMWH tinzaparin. S-NACH or tinzaparin with or without gemcitabine were administered, and tumor luminescent signal intensity, tumor weight, and histopathology were assessed at the termination of the study. S-NACH and LMWH efficiently inhibited tumor growth and metastasis, without any observed bleeding events with S-NACH as compared to tinzaparin. S-NACH distinctly increased tumor necrosis and enhanced gemcitabine response in the mouse pancreatic cancer models. These data suggest the potential implication of S-NACH as a neoadjuvant in pancreatic cancer.

Original language	English
Pages (from-to)	25-33
Number of pages	9
Journal	Cancer Letters
Volume	350
Issue number	1-2
DOIs	https://doi.org/10.1016/j.canlet.2014.04.016
Publication status	Published - Aug 1 2014

Keywords

Anti-cancer
Low molecular weight heparin
Non-anticoagulant heparin
Pancreatic cancer
Tumor suppressor
Tumor survival

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.canlet.2014.04.016

Cite this

@article{aaa08a5899344cf28f9a90d5a131952d,

title = "Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin",

abstract = "Sulfated non-anticoagulant heparins (S-NACHs) might be preferred for potential clinical use in cancer patients without affecting hemostasis as compared to low molecular weight heparins (LMWHs). We investigated anti-tumor effects, anti-angiogenesis effects, and mechanisms of S-NACH in a mouse model of pancreatic cancer as compared to the LMWH tinzaparin. S-NACH or tinzaparin with or without gemcitabine were administered, and tumor luminescent signal intensity, tumor weight, and histopathology were assessed at the termination of the study. S-NACH and LMWH efficiently inhibited tumor growth and metastasis, without any observed bleeding events with S-NACH as compared to tinzaparin. S-NACH distinctly increased tumor necrosis and enhanced gemcitabine response in the mouse pancreatic cancer models. These data suggest the potential implication of S-NACH as a neoadjuvant in pancreatic cancer.",

keywords = "Anti-cancer, Low molecular weight heparin, Non-anticoagulant heparin, Pancreatic cancer, Tumor suppressor, Tumor survival",

author = "Thangirala Sudha and Murat Yalcin and Lin, \{Hung Yun\} and Elmetwally, \{Ahmed M.\} and Tipu Nazeer and Thiruvengadam Arumugam and Patricia Phillips and Mousa, \{Shaker A.\}",

note = "Funding Information: This work was supported by the National Institutes of Health (Grant Number 1R21CA124931-01 to S.A.M.). We appreciate the excellent editing by Dr. Kelly A. Keating, Pharmaceutical Research Institute (PRI) and the technical support by members of the PRI.",

year = "2014",

month = aug,

day = "1",

doi = "10.1016/j.canlet.2014.04.016",

language = "English",

volume = "350",

pages = "25--33",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "1-2",

}

TY - JOUR

T1 - Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin

AU - Sudha, Thangirala

AU - Yalcin, Murat

AU - Lin, Hung Yun

AU - Elmetwally, Ahmed M.

AU - Nazeer, Tipu

AU - Arumugam, Thiruvengadam

AU - Phillips, Patricia

AU - Mousa, Shaker A.

N1 - Funding Information: This work was supported by the National Institutes of Health (Grant Number 1R21CA124931-01 to S.A.M.). We appreciate the excellent editing by Dr. Kelly A. Keating, Pharmaceutical Research Institute (PRI) and the technical support by members of the PRI.

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Sulfated non-anticoagulant heparins (S-NACHs) might be preferred for potential clinical use in cancer patients without affecting hemostasis as compared to low molecular weight heparins (LMWHs). We investigated anti-tumor effects, anti-angiogenesis effects, and mechanisms of S-NACH in a mouse model of pancreatic cancer as compared to the LMWH tinzaparin. S-NACH or tinzaparin with or without gemcitabine were administered, and tumor luminescent signal intensity, tumor weight, and histopathology were assessed at the termination of the study. S-NACH and LMWH efficiently inhibited tumor growth and metastasis, without any observed bleeding events with S-NACH as compared to tinzaparin. S-NACH distinctly increased tumor necrosis and enhanced gemcitabine response in the mouse pancreatic cancer models. These data suggest the potential implication of S-NACH as a neoadjuvant in pancreatic cancer.

AB - Sulfated non-anticoagulant heparins (S-NACHs) might be preferred for potential clinical use in cancer patients without affecting hemostasis as compared to low molecular weight heparins (LMWHs). We investigated anti-tumor effects, anti-angiogenesis effects, and mechanisms of S-NACH in a mouse model of pancreatic cancer as compared to the LMWH tinzaparin. S-NACH or tinzaparin with or without gemcitabine were administered, and tumor luminescent signal intensity, tumor weight, and histopathology were assessed at the termination of the study. S-NACH and LMWH efficiently inhibited tumor growth and metastasis, without any observed bleeding events with S-NACH as compared to tinzaparin. S-NACH distinctly increased tumor necrosis and enhanced gemcitabine response in the mouse pancreatic cancer models. These data suggest the potential implication of S-NACH as a neoadjuvant in pancreatic cancer.

KW - Anti-cancer

KW - Low molecular weight heparin

KW - Non-anticoagulant heparin

KW - Pancreatic cancer

KW - Tumor suppressor

KW - Tumor survival

UR - https://www.scopus.com/pages/publications/84901494319

UR - https://www.scopus.com/inward/citedby.url?scp=84901494319&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2014.04.016

DO - 10.1016/j.canlet.2014.04.016

M3 - Article

C2 - 24769074

AN - SCOPUS:84901494319

SN - 0304-3835

VL - 350

SP - 25

EP - 33

JO - Cancer Letters

JF - Cancer Letters

IS - 1-2

ER -

Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this